Shares of Galena Biopharma Inc (NASDAQ:GALE) ended Thursday session in green amid volatile trading. The shares closed up +0.001 points or 0.22% at $0.277 with 1.62 million shares getting traded. Post opening the session at $0.27, the shares hit an intraday low of $0.26 and an intraday high of $0.28 and the price vacillated in this range throughout the day. The company has a market cap of $57.22 million and the numbers of outstanding shares have been calculated to be 214.50 million shares.
Galena Biopharma Inc (GALE), a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs. The companys lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with trastuzumab for node positive and negative HER2 IHC 3+ patients.
Shares of Pfizer Inc. (NYSE:PFE) ended Thursday session in red amid volatile trading. The shares closed down -0.31 points or -0.94% at $32.76 with 24.18 million shares getting traded. Post opening the session at $32.57, the shares hit an intraday low of $32.52 and an intraday high of $32.90 and the price vacillated in this range throughout the day. The company has a market cap of $198.35 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare.